February 2010 Issue of MMM
Enough of what you can't do online! This has been the mantra at MM&M in the past few weeks, and the brief for this month's ...
So much of the discussion around pharma and social media focuses on what you can't do. Gilead Sciences, Novartis, UCB, Shire and Bayer provide examples ...
Adrienne Fanti and Tracy Peterson take a look back at the extraordinary lives and achievements of the Medical Advertising Hall of Fame's three newest members
Tom Sullivan can often be found in the trenches of the debate over physician-industry relationships, a lonely pro-industry voice squaring off against powerful legislators and ...
The list of top 50 CV products to emerge from "the Aughts" looks set for a shakeup entering "the Tens." Marc Iskowitz examines threats and ...
Patients and families often ask: "Doctor, what would you do if it were you" or "your mother?"
How come vaccine manufacturers take so much heat about flu vaccines? They are blamed for using outdated technologies, delay in shipments and contaminated batches. They ...
Thinking of launching an oncology journal? You may have missed a profitable window.
By this summer, Pfizer plans to deploy tablet PCs to 5,000 primary care, oncology, established products and specialty care reps detailing about 22 products.
In the wake of Merck's merger with Schering-Plough, the company is making staff cuts while hinting of more to come.
Novartis launched schizophrenia med Fanapt to US physicians, following a May 2009 approval.
B2B media firm Lebhar-Friedman sold the journals division of Dowden Health Media to Quadrant HealthCom in a move it said was designed to decrease reliance ...
A JAMA analysis questioning the effectiveness of antidepressants has renewed debate.
Data from Nielsen show that while 99% of video in the US is viewed on traditional TV, DVR and online video use is growing fast. ...
Everyday Health is launching a condition-based "virtual doctor" feature for patients with chronic conditions that emphasizes compliance.
Multimedia diabetes network dLife said total visits to its website crossed the one-million mark for the month of November.
AgaMatrix, which makes the WaveSense line of blood glucose monitoring products, announced that the latest version of its WaveSense Diabetes Manager App will provide users ...
Actonel, the osteoporosis drug from Warner Chilcot-Sanofi Aventis, is takin' it to the streets!
Pharma marketers placed safe bets and sought value in their consumer advertising buys last year, and that cautious approach is sure to continue.
The FDA unveiled the first fruit of its transparency initiative with FDA Basics, a microsite aimed at demystifying the agency's workings for the public.
Sanofi-Aventis is betting its $1.9-billion purchase of Chattem can give it a US marketing platform for future Rx-to-OTC switch brands.
NuvaRing and Latisse lead the pack in DTC-driven traffic to their brand.com sites, according to Manhattan Research.
In the frenzied days of December, as the Senate scrambled to wrap up its version of healthcare reform legislation, pharmas and advertisers overcame a last-minute ...
The number of physicians who like e-detailing dipped nearly 10% from 2008 to 2009, according to a recent study.
IMS Health convened a special meeting to vote on its buyout offer, in what some consider a move to restore investor confidence in the deal.
McCann Healthcare Worldwide announced a new "Office of the CEO" under which four executives will share leadership responsibility.
Cephalon has consolidated its oncology business into Interpublic Group's Draftfcb.
Rosetta, the largest independent digital marketing agency in the US, has acquired Wishbone for an undisclosed sum.
More than a year has elapsed since the Obama administration first promised a more transparent government, but all we have seen at the FDA is ...
A two-year hiring push at the FDA's Center for Drug Evaluation and Research (CDER) has added enough new staff to bring itself back on track ...
Washington Legal Foundation (WLF) and three patient advocacy groups have filed a friend of the court brief in the District of Columbia federal court supporting ...
Rivalries among colleagues in the same company are nothing new. Just watch an episode of The Office, and you'll see.
We have entered a new era that affords Rx marketers opportunities to achieve ROI "beyond the pill" by providing value-added programs and services.
The pharma industry looks to the next decade with trepidation. Growth in many sectors is flat. Generic expiries loom. Trust in the industry is at ...
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.